방사선종양학

본문글자크기
  • [Anticancer Res.] Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients

    전남대화순병원 / 정원기, 김용협*

  • 출처
    Anticancer Res.
  • 등재일
    2023 Apr
  • 저널이슈번호
    43(4):1797-1807.
  • 내용

    바로가기  >

    Abstract
    Background/aim: Pre-treatment interstitial lung abnormality (ILA) is associated with post-cancer treatment adverse events and high mortality rate in lung cancer patients. This study aimed to assess whether ILA affects the survival and development of symptomatic radiation pneumonitis (RP) in unresectable stage III non-small cell lung cancer (NSCLC) patients who had undergone definitive concurrent chemoradiotherapy (CCRT).

    Patients and methods: Data of stage III NSCLC patients who underwent definitive CCRT between January 2010 and November 2017 were retrospectively collected. Univariate and multivariate regression analyses were performed to evaluate the risk factors for symptomatic RP. The association between pre-treatment ILA and survival was assessed using Kaplan-Meier analysis with log-rank test and Cox proportional hazards regression.

    Results: This study included 201 patients (188 men) of a mean age of 64.7±7.3 years. Pre-treatment ILA and fibrotic ILA were observed in 21.9% and 12.9% of the patients, respectively. Symptomatic RP (grade ≥2) occurred in 13.5% of the patients. Fibrotic ILA was a significant risk factor for grade ≥2 RP and grade ≥3 RP (p=0.004 and 0.033, respectively). The survival rate was significantly poorer in patients with fibrotic ILA than in those without ILA. Cox proportional hazards regression revealed that fibrotic ILA was an independent risk factor for mortality (p<0.001).

    Conclusion: Pre-treatment fibrotic ILA is significantly associated with symptomatic RP and poor survival in unresectable stage III NSCLC patients who have undergone definitive CCRT. CCRT should be cautiously performed in patients presenting pre-treatment fibrotic ILA to prevent adverse outcomes.

     

     

    Affiliations

    Won Gi Jeong  1   2 , Yun-Hyeon Kim  1   2 , Sung-Ja Ahn  2   3 , Jae-Uk Jeong  3 , Byung Chan Lee  1 , Ick Joon Cho  2   3 , Yong-Hyub Kim  4   3
    1 Department of Radiology, Chonnam National University Medical School, Gwangju, Republic of Korea.
    2 Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea.
    3 Department of Radiation Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Republic of Korea.
    4 Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea; yonghyeob@gmail.com.

  • 키워드
    Non-small-cell lung cancer; chemoradiotherapy; interstitial; lung diseases; radiation pneumonitis.
  • 편집위원

    비소세포성폐암의 동시항암방사선치료에서 치료전 interstitial lung abnormality (ILA) 여부가 방사선폐렴(RP) 발현에 영향을 미치고 이로 인한 사망률 증가를 보일 수 있음. 이에 따라 해당 연구에서는 201명의 환자를 대상으로 한 후향적 연구를 통해 fibrotic ILA가 2등급 이상의 RP를 유발할 수 있는 유의한 위험인자이며, 생존율에도 영향을 미치는 것으로 확인했음. 따라서, 폐암환자의 동시항암방사선요법 시행 시 fibrotic ILA가 있는 환자에서는 더욱 주의해야 한다는 결론을 얻었음.

    2023-06-02 11:28:29

  • 덧글달기
    덧글달기
       IP : 18.222.200.143

    등록